Literature DB >> 847654

Femoropopliteal bypass for limb salvage.

S R Ramsburgh, S M Lindenauer, T R Weber, R O Kraft, C M Schmidt, W J Fry.   

Abstract

A total of 148 femoropopliteal bypass procedures followed for a minimum of 2 years yielded a patency rate of 61.9 percent among survivors. Diabetes mellitus, cigarette smoking, quality of the outflow, or prior inflow procedures did not influence patency rate. Results were less satisfactory in women and when cloth grafts were used. The indications for femoropopliteal bypass require continuing careful assessment.

Entities:  

Mesh:

Year:  1977        PMID: 847654

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Objective analysis of factors contributing to failure of tibial bypass grafts.

Authors:  J B Ricco; W R Flinn; M D McDaniel; J S Yao; J J Bergan
Journal:  World J Surg       Date:  1983-05       Impact factor: 3.352

2.  Progress in limb salvage by reconstructive arterial surgery combined with new or improved adjunctive procedures.

Authors:  F J Veith; S K Gupta; R H Samson; L A Scher; S C Fell; P Weiss; G Janko; S W Flores; H Rifkin; G Bernstein; H Haimovici; M L Gliedman; S Sprayregen
Journal:  Ann Surg       Date:  1981-10       Impact factor: 12.969

3.  Comparative study on the fibrinolytic activity of pseudointima in varying types of autovein grafting.

Authors:  M Furuyama; A Kusaba; M Moriyama; M Kamori; K Inokuchi
Journal:  Jpn J Surg       Date:  1980-12

4.  Small artery reconstruction with a new vascular prosthesis.

Authors:  D Raithel; H Groitl
Journal:  World J Surg       Date:  1980       Impact factor: 3.352

5.  Results of 100 consecutive femoropopliteal vein grafts for limb salvage.

Authors:  A Naji; J Chu; P R McCombs; C F Barker; H D Berkowitz; B Roberts
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

Review 6.  The Below-Knee Amputation: To Amputate or Palliate?

Authors:  Benjamin J Brown; Christopher E Attinger
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-02       Impact factor: 4.730

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.